MarcERothenbergMD

Allergy & Immunology • Cincinnati, OH

Pediatric Asthma & Allergic Conditions

Professor, Pediatrics, University of Cincinnati College of Medicine

Join to view full profile

Dr. Rothenberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rothenberg's full profile

Already have an account?

Office
3333 Burnet Ave
# MLC2000
Cincinnati, OH 45229
Phone+1 513-636-6771

Fax+1 513-636-2511

Education & Training

Boston Children’s HospitalFellowship, Allergy and Immunology, 1992 - 1994
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1990 - 1992
Harvard Medical SchoolClass of 1990

Certifications & Licensure

OH State Medical License 1997 - 2026
MA State Medical License 1992 - 1997
American Board of Allergy and Immunology Allergy & Immunology
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2000
Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology

Clinical Trials

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Start of enrollment: 2001 Dec 01
Completed
Phase 1, Phase 2
A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Start of enrollment: 2002 Oct 01
Completed
Phase 3
Data Bank for Eosinophilic Disorders Start of enrollment: 2001 May 01
Completed
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
RECRUITING
A Study of Flovent in Patients With Eosinophilic Esophagitis Start of enrollment: 2007 Jan 01
Completed
Phase 2
Eosinophilic Esophagitis Databank Start of enrollment: 2011 Apr 01
Completed
Registry for Eosinophilic Gastrointestinal Disorders (REGID) Start of enrollment: 2012 Nov 01
Completed
Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Start of enrollment: 2013 Oct 10
Completed
Phase 2
An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Start of enrollment: 2017 May 23
Completed
Phase 2
Benralizumab for Eosinophilic Gastritis (BEGS) Start of enrollment: 2018 Apr 23
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Distinct roles for thymic stromal lymphopoietin (TSLP) and IL-33 in experimental eosinophilic esophagitis.
Anish Dsilva, Ariel Wagner, Michal Itan, Natalie Rhone, Shmulik Avlas
Biorxiv. 2025-03-01
Imaging eosinophil secretory granules: From storage containers to active, immune responder organelles.
Rossana C N Melo, Marc E Rothenberg
The Journal of Allergy and Clinical Immunology. 2025-02-01
1 citations
One-food versus 4-food elimination diet for pediatric eosinophilic esophagitis: A multisite randomized trial.
Kara L Kliewer, J Pablo Abonia, Seema S Aceves, Dan Atkins, Peter A Bonis
The Journal of Allergy and Clinical Immunology. 2025-02-01

Journal Articles

Genetic Variants at the 16p13 Locus Confer Risk for Eosinophilic Esophagitis
Robert P Kimberly, Marc E Rothenberg, Patrick M Gaffney, Hugh A Sampson, J Pablo Abonia, Mirna Chehade, Philip E Putnam, Brian P Vickery, Glenn T Furuta, John B Harley, Nature

Press Mentions

New ACG Guideline on EoE Reflects over a Decade of Advances in Diagnosis and ManagementJanuary 22nd, 2025
In EoE, Esophageal Protein Profiles Appear Similar Between PPI-Responsive and Nonresponsive Patients Before TreatmentDecember 18th, 2024
Native American Children, Young Adults with Eosinophilic Esophagitis See Barriers in CareOctober 15th, 2024
Join now to see all

Grant Support

Genetic and Immunological Dissection of Eosinophilic EsophagitisCINCINNATI CHILDRENS HOSP MED CTR2015–2026
Consortium of Eosinophilic Gastrointestinal Disease ResearchersCINCINNATI CHILDRENS HOSP MED CTR2014–2025
Regulation of Gastrointestinal EosinophilsCINCINNATI CHILDRENS HOSP MED CTR1999–2025
Regulation of Gastrointestinal EosinophilsCINCINNATI CHILDRENS HOSP MED CTR1999–2025
Regulation Of Gastrointestinal EosinophilsNational Institute Of Allergy And Infectious Diseases2010–2012
Role Of Desmoglein-1 In Eosinophilic EsophagitisNational Institute Of Allergy And Infectious Diseases2011
IL-13 And Eosinophilic EsophagitisNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
IL-13 Associated Eosinophil Lung ResponsesNational Institute Of Allergy And Infectious Diseases2010–2011
Eosinophilic Esophagitis And Food AllergyNational Institute Of Allergy And Infectious Diseases2010–2011
Epithelial-Derived Eotaxin 3 In Eosinophilic EsophagitisNational Institute Of Allergy And Infectious Diseases2010
A Multi-Center Clinical Trial Of 1760 MCG Of Daily Swallowed Fluticasone Vs. PlacNational Institute Of Allergy And Infectious Diseases2010
IL-13 Associated Eosinophil Lung ResponsesNational Institute Of Allergy And Infectious Diseases2009
A Multi-Center Clinical Trial Of 1760 MCG Of Daily Swallowed Fluticasone Vs. PlacNational Institute Of Allergy And Infectious Diseases2009
IL-13 And Eosinophilic EsophagitisNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2009
Epithelial-Derived Eotaxin 3 In Eosinophilic EsophagitisNational Institute Of Allergy And Infectious Diseases2006–2009
Clinical Trial: Effect Of Intravenous Anti-Il5 (MEPOLIZUMAB) In HypereosinophiliNational Center For Research Resources2008
Role Of Eotaxins And CCR3 In IL-13 Induced AsthmaNational Heart, Lung, And Blood Institute2004–2008
Core--Breeding And GenotypingNational Heart, Lung, And Blood Institute2004–2008
Effect Of Intravenous Anti-Il5 (MEPOLIZUMAB) In Hypereosinophilic SyndromesNational Center For Research Resources2005–2007
Eosinophil, Chemokine And IL-13 Cooperativity In AsthmaNational Institute Of Allergy And Infectious Diseases2004–2007
Role Of Arginase In Allergic Airway InflammationNational Institute Of Allergy And Infectious Diseases2003–2007
Anti-Il 5 For HypereosinophiliaFood And Drug Administration2005
IV Anti-Il5 (MEPOLIZUMAB) In Hypereosinophilic SyndromesNational Center For Research Resources2004
Mechanisms Of Eosinophilia In Experimental AsthmaNational Institute Of Allergy And Infectious Diseases1998–2002